FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128857229> ?p ?o ?g. }

• W2128857229 endingPage "8" @default.
• W2128857229 startingPage "4" @default.
• W2128857229 abstract "Abstract: Derangements in mineral metabolism are known to occur early in the course of chronic kidney disease (CKD). Recent clinical practice guidelines are designed to focus on the problem early in the course of kidney disease, when it is recommended to evaluate the levels of parathyroid hormone (PTH) and to try to intervene early if the levels are elevated. To begin early intervention for hyperparathyroidism in chronic kidney disease will require involvement of primary care physicians and other subspecialty groups to identify the patients at risk and begin to intervene with measures to control hyperparathyroidism and its consequences on mineral metabolism. It has recently been demonstrated that chronic kidney disease is a significant risk factor for vitamin D deficiency and since abnormalities in vitamin D metabolism are important in the generation of hyperparathyroidism, this is an issue that needs direct attention. Studies are needed to assess the effects of correcting this vitamin D deficiency in early CKD. As kidney disease progresses, efforts to control hyperparathyroidism will likely need to be intensified and several therapeutic options are available, such as phosphate binders, repletion of vitamin D, the use of active vitamin D sterols, or the use of vitamin D analogs. In addition, it is important to define the appropriate PTH values that need to be achieved to minimize complications on bone. Such studies are in progress at the present time to validate the current more specific PTH assays. Strict guidelines have been proposed for the management of bone and mineral metabolism in patients with CKD stage V on dialysis, and although these challenging recommendations were initially opinion‐based, there is mounting evidence which provides confirmation of these targets as relevant. Treatment options for patients on dialysis involve the full spectrum of agents which include phosphate binders, active vitamin D sterols (often given parenterally), the use of calcimimetic agents, surgical parathyroidectomy, and evaluation of appropriate levels of dialysate calcium. Similar to early stages of CKD, studies are in progress to refine the PTH targets with the newer PTH assays. With increased focus on the complications of bone and mineral metabolism as part of the continuum of chronic kidney disease, and with a variety of new therapies available, it is anticipated that improved patient outcomes should be achievable in this patient group." @default.
• W2128857229 created "2016-06-24" @default.
• W2128857229 creator A5011328038 @default.
• W2128857229 creator A5055986991 @default.
• W2128857229 creator A5074878046 @default.
• W2128857229 date "2005-02-01" @default.
• W2128857229 modified "2023-10-15" @default.
• W2128857229 title "Challenges in the Therapy of Secondary Hyperparathyroidism" @default.
• W2128857229 cites W1965969760 @default.
• W2128857229 cites W1973835767 @default.
• W2128857229 cites W1978019852 @default.
• W2128857229 cites W1990329250 @default.
• W2128857229 cites W1994057975 @default.
• W2128857229 cites W2010977566 @default.
• W2128857229 cites W2012028303 @default.
• W2128857229 cites W2016011467 @default.
• W2128857229 cites W2023370107 @default.
• W2128857229 cites W2026420466 @default.
• W2128857229 cites W2028302756 @default.
• W2128857229 cites W2031378939 @default.
• W2128857229 cites W2038786617 @default.
• W2128857229 cites W2045847718 @default.
• W2128857229 cites W2057112909 @default.
• W2128857229 cites W2067704553 @default.
• W2128857229 cites W2088255854 @default.
• W2128857229 cites W2105288874 @default.
• W2128857229 cites W2105417592 @default.
• W2128857229 cites W2107207648 @default.
• W2128857229 cites W2119405169 @default.
• W2128857229 cites W2125165329 @default.
• W2128857229 cites W2147175803 @default.
• W2128857229 cites W2152798728 @default.
• W2128857229 cites W2171591197 @default.
• W2128857229 cites W2334049533 @default.
• W2128857229 cites W4213211919 @default.
• W2128857229 cites W4231263233 @default.
• W2128857229 doi "https://doi.org/10.1111/j.1774-9987.2005.00208.x" @default.
• W2128857229 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15828898" @default.
• W2128857229 hasPublicationYear "2005" @default.
• W2128857229 type Work @default.
• W2128857229 sameAs 2128857229 @default.
• W2128857229 citedByCount "10" @default.
• W2128857229 countsByYear W21288572292012 @default.
• W2128857229 countsByYear W21288572292016 @default.
• W2128857229 countsByYear W21288572292022 @default.
• W2128857229 crossrefType "journal-article" @default.
• W2128857229 hasAuthorship W2128857229A5011328038 @default.
• W2128857229 hasAuthorship W2128857229A5055986991 @default.
• W2128857229 hasAuthorship W2128857229A5074878046 @default.
• W2128857229 hasConcept C124490489 @default.
• W2128857229 hasConcept C126322002 @default.
• W2128857229 hasConcept C134018914 @default.
• W2128857229 hasConcept C142724271 @default.
• W2128857229 hasConcept C177713679 @default.
• W2128857229 hasConcept C2775945674 @default.
• W2128857229 hasConcept C2776699218 @default.
• W2128857229 hasConcept C2778653478 @default.
• W2128857229 hasConcept C2778838027 @default.
• W2128857229 hasConcept C2779134260 @default.
• W2128857229 hasConcept C2779740938 @default.
• W2128857229 hasConcept C2780642338 @default.
• W2128857229 hasConcept C2781208988 @default.
• W2128857229 hasConcept C519063684 @default.
• W2128857229 hasConcept C54847362 @default.
• W2128857229 hasConcept C71924100 @default.
• W2128857229 hasConceptScore W2128857229C124490489 @default.
• W2128857229 hasConceptScore W2128857229C126322002 @default.
• W2128857229 hasConceptScore W2128857229C134018914 @default.
• W2128857229 hasConceptScore W2128857229C142724271 @default.
• W2128857229 hasConceptScore W2128857229C177713679 @default.
• W2128857229 hasConceptScore W2128857229C2775945674 @default.
• W2128857229 hasConceptScore W2128857229C2776699218 @default.
• W2128857229 hasConceptScore W2128857229C2778653478 @default.
• W2128857229 hasConceptScore W2128857229C2778838027 @default.
• W2128857229 hasConceptScore W2128857229C2779134260 @default.
• W2128857229 hasConceptScore W2128857229C2779740938 @default.
• W2128857229 hasConceptScore W2128857229C2780642338 @default.
• W2128857229 hasConceptScore W2128857229C2781208988 @default.
• W2128857229 hasConceptScore W2128857229C519063684 @default.
• W2128857229 hasConceptScore W2128857229C54847362 @default.
• W2128857229 hasConceptScore W2128857229C71924100 @default.
• W2128857229 hasIssue "1" @default.
• W2128857229 hasLocation W21288572291 @default.
• W2128857229 hasLocation W21288572292 @default.
• W2128857229 hasOpenAccess W2128857229 @default.
• W2128857229 hasPrimaryLocation W21288572291 @default.
• W2128857229 hasRelatedWork W1967509723 @default.
• W2128857229 hasRelatedWork W1993131509 @default.
• W2128857229 hasRelatedWork W2009354171 @default.
• W2128857229 hasRelatedWork W2014348675 @default.
• W2128857229 hasRelatedWork W2077543700 @default.
• W2128857229 hasRelatedWork W2143390412 @default.
• W2128857229 hasRelatedWork W3113414415 @default.
• W2128857229 hasRelatedWork W4221078803 @default.
• W2128857229 hasRelatedWork W4234999464 @default.
• W2128857229 hasRelatedWork W4301397011 @default.
• W2128857229 hasVolume "9" @default.
• W2128857229 isParatext "false" @default.

• next